Source:http://linkedlifedata.com/resource/pubmed/id/20588178
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
2010-7-28
|
| pubmed:abstractText |
The MECT1/MAML2 translocation is identified in a large proportion of mucoepidermoid carcinomas (MEC) of the salivary gland and is an emerging favorable prognosticator. However, there are conflicting data on this translocation's specificity, restriction to low/intermediate MEC, and strength as a prognosticator. We present our experience with the MECT1/MAML2 translocation in a large cohort of MECs to address these issues. We analyzed 55 salivary MEC and 36 potential MEC mimics (24 Warthin tumors, 5 oncocytomas, 3 squamous cell carcinomas, 2 squamoid salivary duct carcinomas, 1 lymphoepithelial cyst, 1 Schneiderian carcinoma ex papilloma) for presence of the MECT1/MAML2 translocation by fluorescent in-situ hybridization (FISH) and real-time RT-PCR. Overall, MECT1/MAML2 translocation was present in 36/55 (66%) of MEC whereas all 36 non-MEC were negative for translocation. Low or intermediate-grade MEC had a higher frequency of translocation (75%) than high-grade MEC (46%) (P=0.039). Translocation positive cases had a better disease-specific survival (log rank P=0.026) although 2 patients still died of disease. Within high-grade MEC, MECT1/MAML2 positive tumors had lower rates of anaplasia (P=0.001), and mitotic counts (P=0.012). Thus, MECT1/MAML2 translocation is highly specific for MEC and imparts a better prognosis. However, it is frequent even within high-grade MEC and can be seen in lethal cases suggesting that translocation status should not supersede conventional parameters. There are 2 distinct subgroups within high-grade MEC, and the translocation negative tumors may actually be more appropriately categorized as another tumor type (such as adenosquamous carcinoma).
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
1532-0979
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
34
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1106-21
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:20588178-Adolescent,
pubmed-meshheading:20588178-Adult,
pubmed-meshheading:20588178-Aged,
pubmed-meshheading:20588178-Aged, 80 and over,
pubmed-meshheading:20588178-Carcinoma, Mucoepidermoid,
pubmed-meshheading:20588178-Chi-Square Distribution,
pubmed-meshheading:20588178-Child,
pubmed-meshheading:20588178-Disease-Free Survival,
pubmed-meshheading:20588178-Female,
pubmed-meshheading:20588178-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:20588178-Humans,
pubmed-meshheading:20588178-In Situ Hybridization, Fluorescence,
pubmed-meshheading:20588178-Kaplan-Meier Estimate,
pubmed-meshheading:20588178-Male,
pubmed-meshheading:20588178-Middle Aged,
pubmed-meshheading:20588178-Neoplasm Staging,
pubmed-meshheading:20588178-Oncogene Proteins, Fusion,
pubmed-meshheading:20588178-Prognosis,
pubmed-meshheading:20588178-Retrospective Studies,
pubmed-meshheading:20588178-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:20588178-Salivary Gland Neoplasms,
pubmed-meshheading:20588178-Time Factors,
pubmed-meshheading:20588178-Translocation, Genetic,
pubmed-meshheading:20588178-Young Adult
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas.
|
| pubmed:affiliation |
Pathology and Laboratory Medicine, University of Pittsburgh, Pittsburgh, PA, USA. seethalarr@upmc.edu
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|